Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Immunization Schedules


Section Navigation
			
			CDC Home








Schedule Changes & Guidance						Print
																Related Pages
										**On This Page**
			Child and Adolescent Immunization Schedule ChangesVaccine Catch-Up GuidanceAdult Immunization Schedule Changes
		


Open All Close AllChild and Adolescent Immunization Schedule Changes for 2024General schedule
	Added 20- valent pneumococcal conjugate vaccine (PCV20), Mpox vaccine (Jynneos), RSV monoclonal antibody (nirsevimab), RSV vaccine (Abrysvo), and meningococcal groups A, B, C, W, Y (Penbraya).
Deleted bivalent mRNA COVID-19 vaccines, diphtheria and tetanus Toxoid Adsorbed vaccine (DT), 13-valent pneumococcal conjugate vaccine (PCV13), and meningococcal groups A, C, W, Y polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D, Menactra)
Added RSV and Mpox to the list of vaccines excluded from the vaccine injury compensation program (VICP)
Added Mpox vaccine to the list of vaccines covered by the Countermeasures Injury Compensation Program (CICP)
Added a new Addendum section to summarize new and updated ACIP recommendation that will occur after the 2024 child and adolescent immunization schedule is published.COVID-19 vaccination
	The COVID-19 note was revised to provide guidance for use of updated (2023–2024 Formula) COVID-19 vaccines.DTaP vaccination
	The DTaP note was revised to clarify primary and booster dosesHPV vaccination
	The routine vaccination section was revised to clarify additional doses are not recommended for persons who have completed HPV vaccination series with any valency using the recommended dosing intervals.Influenza vaccination
	The influenza note was updated to reflect the recommendations for the 2023-24 influenza season. In the “Special situations” section, all bullets describing recommendations for persons with a history of egg allergy have been deleted. A note has been added clarifying persons with a history of egg allergy of any severity can be vaccinated with any influenza vaccine indicated for the recipient’s age and health status with no additional safety considerations.MMR vaccination
	The MMR note was updated to clarify when MMRV is used for routine, catch-up vaccination, or in “Special situations”, the minimum interval between doses is 3 months.Meningococcal ACWY vaccination
	MenACWY-D (Menactra) has been removed from all sections. Information on recommendation for the use of the newly licensed meningococcal A, B, C, W, Y vaccine have also been included.MenB vaccination
	Information about the use of the newly licensed meningococcal A, B, C, W, Y vaccine has been added. A resource to assist healthcare providers with shared clinical decision-making recommendations for MenB vaccination has also been included.Mpox vaccination
	An Mpox note was added to provide guidance for use of Jynneos in adolescents age 18 years based on sexual risk factors.Pneumococcal vaccination
	PCV13 has been deleted from all sections. The routine vaccination, catch-up vaccination, and “Special situations” sections have been updated with the new recommendations for use of 15-valent pneumococcal conjugate vaccine (PCV15), PCV20, and PPSV23. Chronic kidney disease, chronic liver disease, and moderate persistent or severe persistent asthma were added to the list of medical conditions that increase the risk for invasive pneumococcal disease.Poliovirus vaccination
	The “Catch up” vaccination has been revised to include updated recommendations for adolescents age 18 years. The recommendations for adolescents age 18 years who are at increased risk for exposure to poliovirus and have completed the primary series have also added.Respiratory syncytial virus immunization
	A note was added to provide details on the use of nirsevimab in infants and young children. Additionally, information describing timing of immunization including guidance for jurisdictions with RSV seasonality that differs from most of the continental United States was added.Respiratory syncytial virus vaccination
	A note was added to provide details on the use of RSV vaccine during pregnancy. Abrysvo is the only RSV recommended for use during pregnancy. Information describing timing of vaccination including guidance for jurisdictions with RSV seasonality that differs from most of the continental United States has also been included.Tdap vaccination
	The Tdap note was revised to clarify that the Tdap dose recommended at age 11–12years is the adolescent Tdap booster dose.Appendix
	COVID-19 row: added new rows describing the contraindications and precautions to mRNA and protein subunit COVID-19 vaccination
DTaP and DT row: deleted DT because this vaccine is no longer distributed in the United States.
Hib row: removed history of severe allergic reaction to dry natural latex from the “Contraindicated or Not Recommended” column
Meningococcal ACWY row: Menactra has been removed because this product is no longer distributed in the United States.
Meningococcal ABCWY row: added a new row describing the contraindications and precautions to MenABCWY vaccination
RSV-mAb (nirsevimab) row: added a new row describing the contraindications and precautions to nirsevimab immunization.
RSV row: added a new row describing the contraindications and precautions to RSV vaccination
Shared Clinical Decision-MakingHPV Vaccination for Adults Aged 27-45 Years [1 page]
Meningococcal B Vaccination [1 page]
Vaccine Catch-Up GuidanceCDC has developed catch-up guidance job aids to assist healthcare providers in interpreting Table 2 in the child and adolescent immunization schedule.
Pneumococcal Conjugate Vaccine (PCV) Catch-Up Guidance for Children 4 Months through 4 Years of Age [3 pages]
*Haemophilus influenzae* type b-Containing Vaccines Catch-Up Guidance for Children 4 Months through 4 Years of Age
Hib vaccine products: ActHIB, Hiberix, Pentacel, Vaxelis, or Unknown [3 pages]
Hib vaccine products: PedvaxHIB only [2 pages]
Diphtheria-, Tetanus-, and Pertussis-Containing Vaccines Catch-Up Guidance for Children 4 Months through 6 Years of Age [2 pages]
Inactivated Polio Vaccine (IPV) [2 pages]
Tetanus-, Diphtheria-, and Pertussis-Containing Vaccines Catch-Up Guidance for Children 7 through 9 Years of Age [2 pages]
Tetanus-, Diphtheria-, and Pertussis-Containing Vaccines Catch-Up Guidance for Children 10 through 18 Years of Age [2 pages]
Top of PageAdult Immunization Schedule Changes for 2024General schedule
	Added Mpox vaccine (Jynneos), RSV vaccines (Abrysvo and Arexvy), and meningococcal groups A, B, C, W, Y (Penbraya)
Deleted bivalent mRNA COVID-19 vaccines and meningococcal groups A, C, W, Y polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D, Menactra)
Added RSV and Mpox to the list of vaccines excluded from the vaccine injury compensation program (VICP)
Added Mpox vaccine to the list of vaccines covered by the Countermeasures Injury Compensation Program (CICP)
Added a new Addendum section to summarize new and updated ACIP recommendations occurring after the 2024 adult immunization schedule is published.COVID-19 vaccination
	The COVID-19 note was revised to provide guidance for use of updated (2023–2024 Formula) COVID-19 vaccines.Hepatitis A vaccination
	The note was revised to clarify that any person who is not fully vaccinated and requests vaccination can receive HepA.Hepatitis B vaccination
	The note was updated to describe the risk-based vaccination recommendation for persons 60 years of age and older. Information on the shared clinical decision-making recommendation for persons 60 years of age and older with diabetes has also been added.HPV vaccination
	The routine vaccination section was revised to clarify additional doses are not recommended for persons who have completed HPV vaccination series with any valency using the recommended dosing intervals. Additionally, a hyperlink to a resource describing shared clinical decision-making recommendations for HPV vaccination was provided to assist healthcare providers.Influenza vaccination
	The influenza note was updated to reflect the recommendations for the 2023-24 influenza season. In the “Special situations” section, all bullets describing recommendations for persons with a history of egg allergy have been deleted. A note has been added clarifying persons with a history of egg allergy of any severity can be vaccinated with any influenza vaccine indicated for the recipient’s age and health status with no additional safety considerations.Meningococcal vaccination
	MenACWY-D (Menactra) has been removed from all sections.  Information on recommendation for the use of the newly licensed meningococcal A, B, C, W, Y vaccine and a resource to assist healthcare providers with shared clinical decision-making recommendations for MenB vaccination have also been included.Mpox vaccination
	An Mpox note was added to provide guidance for use of Jynneos in adults based on sexual risk factors.Pneumococcal vaccination
	The routine vaccination and “Special situations” sections were revised to provide clarity on the guidance and minimum intervals between pneumococcal vaccine doses.Poliovirus vaccination
	The poliovirus vaccination note was updated to add the routine recommendations for adults who are known or suspected to be unvaccinated or incompletely vaccinated to complete the 3-dose IPV primary series. The recommendation for adults who are at increased risk for exposure to poliovirus and have completed the primary series was also added.Respiratory syncytial virus vaccination
	Details were provided on the use of RSV vaccine during pregnancy and in adults 60 years of age and older. Information describing timing of vaccination including guidance for jurisdictions with RSV seasonality that differs from most of the continental United States has also been included. Another note was added that lists the risk factors and medical conditions that healthcare providers should consider when thinking about a patient’s risk for severe RSV disease and if such patients would benefit from vaccination. Finally, a hyperlink to a resource describing shared clinical decision-making recommendations for RSV vaccination among patients 60 years of age and older was provided.Tdap vaccination
	The Tdap note was revised to clarify that a dose of Tdap received at 10 years of age may be counted as the adolescent dose that is routinely recommended at age 11-12 years.Appendix
	COVID-19 row: added new rows describing the contraindications and precautions to mRNA and protein subunit COVID-19 vaccination
Hib row: removed history of severe allergic reaction to dry natural latex from the “Contraindicated or Not Recommended” column
MenACWY row: Menactra has been removed because this product is no longer distributed in the United States.
Meningococcal ABCWY row: added a new row describing the contraindications and precautions to MenABCWY vaccination
RSV row: added a new row describing the contraindications and precautions to RSV vaccinationTop of PageMore Schedule ResourcesPneumoRecs VaxAdvisor Mobile App for Vaccine Providers
CDC Vaccine Schedules App for Healthcare Providers
Epidemiology of Vaccine Preventable Diseases:
The Pink Book Course Textbook
Pink Book Webinar Series
							
					
							Last Reviewed:  November 16, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeSchedules Home
For Healthcare Providersplus icon
Child & Adolescent Immunization Scheduleplus icon
Vaccines in the Schedule
Table 1 – By Age
Table 2 – Catch-up
Table 3 – By Medical Indication
Notes
Appendix
Addendum
Adult Immunization Scheduleplus icon
Vaccines in the Schedule
Table 1 – By Age
Table 2 – By Medical Indication
Notes
Appendix
Addendum
Schedule Changes & Guidance
Resourcesplus icon
Schedule-Related Resources
For You and Your Familyplus icon
Schedule for Infants and Children (Birth – 6 Years)
Schedule for Preteens and Teens (7 Years – 18 Years) Vaccines & ImmunizationsACIP Vaccination RecommendationsGeneral Acronyms and AbbreviationsVaccine Guidelines and Recommendations for Emergency SituationsDelays in Vaccine Supply


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue